Elan Corporation

Elan Corporation was a major biotechnology company that operated globally, with its headquarters in Dublin, Ireland. The company was founded in 1969 by Donald Panoz, an American entrepreneur, and initially focused on the development of pharmaceuticals and biotechnology products. Elan Corporation was listed on the New York Stock Exchange and the Irish Stock Exchange, and was a constituent of the S&P 500 index. The company's research and development efforts were focused on the creation of innovative treatments for various diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, in collaboration with Biogen, Pfizer, and Johnson & Johnson.

● History

The history of Elan Corporation dates back to 1969, when it was founded by Donald Panoz in Athlone, Ireland. Initially, the company focused on the development of pharmaceuticals and biotechnology products, and it quickly established itself as a major player in the industry. In the 1980s, Elan Corporation began to expand its operations globally, with the establishment of subsidiaries in the United States, Europe, and Asia. The company's growth was fueled by its innovative approach to research and development, which involved collaborations with leading universities, such as Harvard University, Stanford University, and University of California, Berkeley, as well as research institutions, including the National Institutes of Health and the European Molecular Biology Laboratory. Elan Corporation's products were marketed and distributed by major pharmaceutical companies, including GlaxoSmithKline, AstraZeneca, and Merck & Co..

● Products and Services

Elan Corporation developed and marketed a range of innovative products and services, including Tysabri, a treatment for multiple sclerosis and Crohn's disease, which was developed in collaboration with Biogen. The company's product portfolio also included Maxipime, an antibiotic used to treat bacterial infections, and Prialt, a treatment for chronic pain, which was developed in partnership with Eisai and Allergan. Elan Corporation's products were approved by regulatory authorities, including the US Food and Drug Administration and the European Medicines Agency, and were marketed and distributed globally, with a significant presence in North America, Europe, and Asia. The company's services included contract manufacturing and contract research, which were provided to major pharmaceutical companies, including Pfizer, Johnson & Johnson, and Novartis.

● Research and Development

Elan Corporation's research and development efforts were focused on the creation of innovative treatments for various diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The company's research and development activities involved collaborations with leading research institutions, including the National Institutes of Health, the European Molecular Biology Laboratory, and the University of Oxford. Elan Corporation's research and development pipeline included a range of promising products, including bapineuzumab, a treatment for Alzheimer's disease, which was developed in collaboration with Johnson & Johnson and Pfizer. The company's research and development efforts were recognized by major awards, including the Albany Medical Center Prize and the Warren Alpert Foundation Prize.

● Financial Information

Elan Corporation was a publicly traded company, listed on the New York Stock Exchange and the Irish Stock Exchange. The company's financial performance was strong, with significant revenue growth and profitability. Elan Corporation's revenue was generated from the sale of its products, including Tysabri and Maxipime, as well as from royalty payments and milestone payments from its partners, including Biogen and Eisai. The company's financial performance was recognized by major financial institutions, including Morgan Stanley, Goldman Sachs, and JPMorgan Chase.

● Controversies and Issues

Elan Corporation was involved in several controversies and issues, including a major accounting scandal in 2002, which led to the resignation of the company's chief executive officer and the restatement of its financial results. The company was also involved in a patent dispute with Biogen over the ownership of Tysabri, which was resolved through a settlement agreement. Elan Corporation was also criticized for its pricing practices, particularly with regard to its multiple sclerosis treatment, Tysabri, which was considered to be one of the most expensive treatments for the disease. The company's controversies and issues were widely reported by major media outlets, including The New York Times, The Wall Street Journal, and Bloomberg.

● Merger and Acquisition

In 2013, Elan Corporation was acquired by Perrigo Company, a major pharmaceutical company, in a deal worth approximately $8.6 billion. The acquisition was completed in December 2013, and Elan Corporation ceased to exist as a separate entity. The acquisition was widely reported by major media outlets, including The New York Times, The Wall Street Journal, and Bloomberg. The deal was also recognized by major financial institutions, including Morgan Stanley, Goldman Sachs, and JPMorgan Chase. Following the acquisition, Perrigo Company continued to market and distribute Elan Corporation's products, including Tysabri and Maxipime, and also retained the company's research and development pipeline, including bapineuzumab. Category:Biotechnology companies